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The nonstructural protein 1 (A/NS1) of influenza A
viruses (IAV) harbors several src homology (SH)–
binding motifs (bm) that mediate interactions with
cellular proteins. In contrast to the sequence variabil-
ity of the second SH3bm, tyrosine 89, within the
SH2bm is a highly conserved residue among IAV
strains. This prompted us to evaluate the necessity of
this SH2bm for IAV virulence. In an in vivo mouse
model, we observed drastic reductions in weight loss,
mortality, and virus titers in lung and bronchoalveo-
lar lavage fluid after infection with the mutant virus
PR8 A/NS1-Y89F (PR8 Y89F) when compared with
wild-type virus (PR8 wt). Concomitantly, we observed
decreased inflammation and less severe pathologic
changes, reflecting reduced levels of virus titers. At
histologic analysis, lungs infected with PR8 wt virus
showed widespread destruction of the bronchiolar
epithelium, with extensive distribution of virus anti-
gen within tracheal, bronchial, bronchiolar, and alve-
olar epithelium. In marked contrast, the bronchiolar
epithelium after infection with the mutant PR8 Y89F
virus was entirely intact, and the severity and extent
of viral infection was reduced and strongly restricted
to alveoli. These findings demonstrate that change of
a single residue of the highly conserved SH2bm
within the A/NS1 results in restricted virus spread in
mouse lung and strongly reduced virulence, which
illustrates the necessity of the SH2bm for IAV-induced
pathogenicity. (Am J Pathol 2012, 180:2361–2374; http://
dx.doi.org/10.1016/j.ajpath.2012.02.029)As estimated by theWorld Health Organization, infections of
the respiratory tract are responsible for greater than 6% of
all deaths worldwide. Among all pathogens that can infect
the respiratory tract, influenza A viruses (IAV) are among the
most common and devastating.1,2 Infections due to these
pathogens are responsible for thousands of hospitalizations
and an enormous economic loss each year. In addition to
seasonal outbreaks, IAV have the potential to cause pan-
demics with several million victims, such as the “Spanish
flu” outbreak in 1918.3 Furthermore, IAV continue to be
discussed as potential causative agents for upcoming life-
threatening pandemics.4
IAV are characterized by a segmented single-stranded
RNA genome with negative orientation. The genome en-
codes as many as 12 viral structural and nonstructural
proteins. The nonstructural protein 1 of IAV (A/NS1) is
encoded by the shortest of the eight gene segments,
along with the nuclear export protein NS2.5
The A/NS1 protein is an important pathogenicity deter-
minant of IAV via interference with the immune response
of the host cell.5 One hallmark of the A/NS1 function is
suppression of the antiviral acting type I interferon (IFN)
system6–8 via interplay with RNA-induced signaling and
binding to host–cell proteins such as the tripartite motif
protein TRIM25.9 Furthermore, A/NS1 inhibits antiviral
acting cellular proteins such as PKR (RNA-activated pro-
tein kinase) via direct binding.10,11 After transcription, the
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via binding to CPSF30,12 but is likewise involved in en-
hancement of viral mRNA translation.13
Studies in mice have revealed that IAV are able to
replicate for almost 2 days after infection before an effi-
cient innate immune response occurs. This is in clear
contrast to NS1-deficient IAV, which trigger rapid and
massive inflammatory responses in the lungs, illustrating
the strong impairing effect of A/NS1 on induction of innate
immune responses after IAV infection.14
In addition to A/NS1-mediated inhibition of innate im-
munity, A/NS1 also indirectly leads to impaired induction
of the adaptive immune response to IAV infection. Fer-
nandez-Sesma et al15 reported that IAV infection of hu-
man-derived primary dendritic cells limited the induction
of several genes connected to dendritic cell maturation,
migration, and T-cell stimulatory activity. As a conse-
quence, IAV-infected dendritic cells were inefficient in
maturation, and failed to stimulate the secretion of IFN-
by helper T cells,15 illustrating the blocking effect of
A/NS1 on T-cell stimulation.
In addition to the described suppressive properties of
A/NS1 regarding induction of immunity after IAV infection,
A/NS1 also activates signaling factors such as phospha-
tidylinositol 3-kinase (PI3K).16–18 Activation of PI3K sig-
naling is mediated by direct interaction of A/NS1 with the
regulatory subunit p85 of PI3K.16,17,19 In addition to these
described interactions, direct binding of A/NS1 to multi-
ple additional cellular proteins has been described.5
A/NS1 is a multifunctional protein consisting of an RNA-
binding domain and several protein–protein interaction mo-
tifs including three src homology (SH) binding motifs (bm),
one SH2bm and two SH3bm.20 During the last several
years, multiple studies have focused on the effects of the
various SHbm within A/NS1 on binding to cellular proteins,
predominantly to p85 of PI3K. Insofar as A/NS1 interaction
with the p85 subunit of PI3K, involvement of the SH2bm
and the first SH3bm within A/NS1 has been demonstra-
ted,16,18,20–24 and Hale et al16 have highlighted the effect of
the residue Y89 within the SH2bm on A/NS1–p85 interac-
tion. The necessity of tyrosine residue 89 within the SH2bm
of A/NS1 is in line with the function-determining character of
the tyrosine residue in functional SH2bm.25
The SHbm within A/NS1 differ in their evolutionary con-
servation on amino acid levels. The functional second
SH3bm (aa212–217) is highly conserved in avian IAV
strains, but is uncommon in IAV of human origin.26 This is
linked to different binding properties to cellular pro-
teins of the Crk family of adaptor proteins,26 which are
involved in regulation of the antiviral acting JNK sig-
naling pathway.27 In contrast to the sequence variabil-
ity of the second SH3bm, the function-determining ty-
rosine 89 within the SH2bm is highly conserved among
many IAV strains including human H5 and H7 strains
and pandemic H1N1v strains.
The major effect of A/NS1 on IAV virulence, combined
with the strong conservation of tyrosine 89 within the
SH2bm, prompted us to analyze the contribution of this
SH2bm for IAV virulence in an in vivomouse model. Herein,
we demonstrate that the highly conserved SH2bm within
A/NS1 of IAV is crucial for efficient replication of IAV in vitroand in vivo. Furthermore, disruption of this motif restricts
virus distribution in the entire mouse lung, limits replication
almost entirely to the alveoli, reduces the inflammatory re-
sponse and pathologic changes in the lung, and results in
dramatically reduced virulence.
Materials and Methods
Cells, Viruses, and Infection Conditions
MDCK (Madin-Darby canine kidney) cells were cultured
in minimal essential medium, and the human lung epithe-
lial cell line (A549), human embryonic kidney cells
(HEK293), and murine lung epithelial cell line (ASB-XIV)
were cultivated in Dulbecco’s modified Eagle’s medium.
Cell culture media were supplemented with 10% heat-
inactivated fetal bovine serum. The human recombinant
influenza virus A/Puerto Rico/8/34 (PR8), wild type (PR8
wt) and the corresponding mutant virus recombinant
A/PR8 A/NS1-Y89F (PR8 Y89F) (PR8-NS1-Y89F forward,
5=-TACCTGCGTCGCGTTTCCTAACTGACATGAC-3=, and
PR8-NS1-Y89F reverse, 5=-GTCATGTCAGTTAGGAAACG-
CGACGCAGGTA-3=) were generatedby using thepHW2000-
based reverse genetic system,28 as described earlier,27
and propagated on 11-day-old embryonated chicken
eggs or MDCK cells. The presence and correctness of
the desired mutation was confirmed via sequencing. The
primary experiments were repeated using two indepen-
dently rescued viruses. The infection procedure of cells
was conducted as described earlier.27
Standard Plaque Titration
Supernatants of infected cells were collected at specified
times after infection, and were used to assess the number
of infectious particles (plaque titers) in the samples, as
described previously.27
Western Blot Analysis, Antibodies, and
Immunoprecipitation
After treatment, cells were lysed on ice for 30 minutes
using radioimmunoprecipitation assay lysis buffer: 25
mmol/L Tris HCl (pH 8.0), 137 mmol/L NaCl, 10% glyc-
erol, 0.1% SDS, 0.5% deoxycholate, 1% NP40, 2 mmol/L
EDTA (pH 8.0), 5 g/mL leupeptin, 5 g/mL aprotinin, 0.2
mmol/L pefablock, 1 mmol/L sodium vanadate, and 5
mmol/L benzamidine. Cell lysates were cleared from de-
bris via centrifugation, and the Bradford method was
used for determination of protein concentrations. Cell
lysates were used for analysis of protein expression using
Western blot analysis. For immunoprecipitation, cells
were lysed on ice for 30 minutes using Triton lysis buffer:
20 mmol/L Tris HCl (pH 7.4), 137 mmol/L NaCl, 10%
glycerol, 1% Triton X-100, 2 mmol/L EDTA, 50 mmol/L
sodium glycerophosphate, 20 mmol/L sodium pyrophos-
phate, 5 g/mL leupeptin, 5 g/mL aprotinin, 0.2 mmol/L
pefablock, 1 mmol/L sodium vanadate, and 5 mmol/L
benzamidine. Cell lysates were processed as described
above. For immunoprecipitation, anti-A/NS1 mouse
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Institute of Molecular Virology, Muenster, Germany) cou-
pled to protein G agarose (Roche Pharma AG, Grenzach-
Wyhlen, Germany) was used. Serum from non-immu-
nized mice was used as control. For immunoprecipitation
input controls, lysates were directly subjected to SDS-
PAGE and Western blot analysis.
Activation of the PI3K pathway was monitored via de-
tection of Akt phosphorylation using a specific anti-
Akt(pS473) rabbit monoclonal antibody (Biosource; Invit-
rogen Corp., Carlsbad, CA). A/NS1 was visualized using
an anti-A/NS1 mouse monoclonal antibody (clone NS1-
23-1; developed at the Institute of Molecular Virology) or
an anti-A/NS1 rabbit polyclonal antibody (provided by Dr.
Thorsten Wolff, Robert-Koch-Institut, Berlin, Germany).
To detect the p85 subunit of PI3K, an anti-p85 mouse
monoclonal antibody (AbD Serotec, Düsseldorf, Ger-
many) was used. For loading controls, an anti-ERK2 (C-
14) rabbit polyclonal antibody (Santa Cruz Biotechnol-
ogy, Inc., Heidelberg, Germany) and an anti-Akt rabbit
polyclonal antibody (Biosource) were used. Protein
bands were visualized using a standard enhanced
chemiluminescence reaction.
Viral RNA Isolation, Transient Transfections, and
Plasmids
For extraction of genomic viral RNA (vRNA), the super-
natant of infected MDCK cells was cleared via centrifu-
gation and subjected to two steps of sterile filtration (filter
diameters, 0.45 and 0.2 m). The virus particles were
pelleted via ultracentrifugation, and were re-dissolved in
PBS before vRNA was isolated using the peqGOLD Viral
RNA Kit (peqLab Biotechnologie GmbH, Erlangen, Ger-
many). Cells were transfected with lipofectamine 2000
(Invitrogen GmbH, Darmstadt, Germany) according to
the protocol of Basler et al.29 p85 was expressed in 293
cells from the plasmid pCMV6-xL6-p85 (OriGene Tech-
nologies, Inc., Rockville, MD). After 24 hours of incuba-
tion at 37°C with 5% CO2, cells were infected and furt-
her treated for immunoprecipitation. The plasmids
pcDNA3–PR8-NS1 wild type and pcDNA3-NS1-Y89F
were used for overexpression of the corresponding
proteins in A549 cells. Empty vector was used as con-
trol. After 24 hours, cells were transfected with vRNA
(500 ng per 12-well).
Isolation of RNA and Quantitative Real-Time PCR
Total RNA from treated or untreated cells was isolated
using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Ger-
many) according to the manufacturer’s protocol. For re-
verse transcription of mRNA, 1 g total RNA and 0.5 g
oligo(dT) primer in a total volume of 12 L were heated
for 10 minutes at 70°C. Enzyme mix was prepared [5
enzyme buffer (Fermentas GmbH, St. Leon-Rot, Ger-
many), H2O, and 500 mol/L deoxyribonucleotide
triphosphate] and incubated at room temperature for 5
minutes before 535 U/100 L RevertAid H Minus M-MuLV
(Fermentas) was added to start reverse transcription at42°C for 1 hour. Inactivation of reverse transcription was
performed at 70°C for 5 minutes. For the quantitative PCR
(qPCR) reaction, Brilliant QPCR SYBR Green Master Mix
(Stratagene Division, Agilent Technologies, Inc., Santa
Clara, CA) was used according to the manufacturer’s in-
structions. Relative RNA concentrations were determined
after 40 cycles of amplification by using the 2CT
method.30 The housekeeping gene GAPDH served as in-
ternal standard. The following primers were used: GAPDH
forward, 5=-GCAAATTTCCATGGCACCGT-3=, and GAPDH
reverse, 5=-GCCCCACTTGATTTTGGAGG-3=; IFN- for-
ward, 5=-GGCCATGACCAACAAGTGTCTCCTCC-3=, and
IFN- reverse, 5=-GCGCTCAGTTTCGGAGGTAACCTGT-3=;
and IL-6 forward, 5=-AGAGGCACTGGCAGAAAACAAC-3=,
and IL-6 reverse, 5=-AGGCAAGTCTCCTCATTGAATCC-3=.
Mouse Experiments
All mouse studies were performed in compliance with
animal welfare regulations (reference No. Az 8.87-
50.10.36.09.007 from the State Agency for Nature, Envi-
ronment, and Consumer Protection, Germany) and un-
der an animal protocol approved by the Animal Care
and Use Committee of St. Jude Children’s Research
Hospital. Eight-week-old BALB/c mice (Harlan-Winkel-
mann GmbH, Borchen, Germany, or Jackson Laboratory,
Bar Harbor, ME) were used for the mouse studies. The
animals were anesthetized via intraperitoneal injection of
250 L of a 1:1 mixture of 10% ketamine and 2% xylazine
(both from Ceva Tiergesundheit GmbH, Düsseldorf, Ger-
many) diluted 1:10 in PBS, and then were infected intra-
nasally with the indicated viruses and plaque-forming
units (PFU) in a 50 L volume. Mice were monitored daily
for disease symptoms, weight, and lethality. The mouse
lethal dose (MLD50) was calculated according to the
protocol of Reed and Muench.31 In accordance with pro-
tection of animal welfare restrictions, mice were sacri-
ficed after weight loss of 25%.
Determination of Virus Titers and Cytokine and
Chemokine Levels in Mouse Lungs
For measurement of virus titers in infected mouse lungs,
mice were sacrificed at specified times after infection,
and lungs were collected in PBS. The lungs were homog-
enized using a FastPrep-24 homogenizer with Lysing Ma-
trix D (both from MP Biomedical LLC, Illkirch, France),
and were adjusted with PBS to obtain a 10% tissue ho-
mogenate. The samples were centrifuged, and the su-
pernatants were used for virus titer determination in stan-
dard plaque titration.
For analyzing cytokine and chemokine levels in total
mouse lung, after sacrifice of mice at the specified times
after infection, the lungs were collected in Trizol, and
RNA was isolated using a modification of the RNAzol
method.32 Reverse transcription and qPCR reactions
were conducted as described above.
The housekeeping gene GAPDH served as internal stan-
dard. The following primers were used: GAPDH forward,
5=-TGACCACAGTCCATGCCATC-3=, and GAPDH reverse,
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TTAAAAACCTGGATCGGAACCAA-3=, andMCP-1 reverse,
5=-GCATTAGCTTCAGATTTACGGGT-3=; TNF- forward,
5=-CCCTCACACTCAGATCATCTTCT-3=, and TNF- re-
verse, 5=-GCTACGACGTGGGCTACAG-3=; IL-6 forward,
5=-TAGTCCTTCCTACCCCAATTTCC-3=, and IL-6 reverse,
5=-TTGGTCCTTAGCCACTCCTTC-3=; MIP-1 forward, 5=-
TTCTCTGTACCATGACACTCTGC-3=, and MIP-1 reverse,
5=-CGTGGAATCTTCCGGCTGTAG-3=; and MIP-1 for-
ward, 5=-TTCCTGCTGTTTCTCTTACACCT-3=, and MIP-1
reverse 5=-CTGTCTGCCTCTTTTGGTCAG-3=.
BALF Collection, Virus Titration, Pathologic
Marker, and Flow Cytometry
After mice were sacrificed, the trachea was exposed and
cannulated using an 18-gauge plastic catheter (BD In-
syte; Becton Dickinson GmbH, Heidelberg, Germany).
Lungs were lavaged five times using 600 L cold sterile
PBS (0.5 mmol/L EDTA and 1% fetal calf serum). For
determining the total protein and lactate dehydrogenase
(LDH) concentrations as markers for pathologic changes
in the lung, BALF was collected using PBS not supple-
mented with EDTA and fetal calf serum. After collection of
BALF, cells were centrifuged, and the supernatant was
used for virus titer determination via a standard plaque
assay, for total protein concentration via the Bradford
assay (Bio-Rad Laboratories GmbH, Munich, Germany),
and for LDH via an LDH assay (Sigma Corp., St. Louis,
MO) according to the manufacturer’s protocol.
After red blood cell lysis, the number of total cells in
BALF was determined (Countess Automated Cell Coun-
ter; Invitrogen Corp.). Flow cytometry (FACSCalibur; Bec-
ton Dickinson GmbH) was performed on the BALF cell
suspensions via staining with F4/80 (FITC), MHCII (PE),
CD11c (PECy7), Gr1 (APC), CD3 (FITC), and CD4
(PECy7) (all from eBiosciences, Frankfurt, Germany), and
CD8 (PE) (Becton Dickinson GmbH). The percentage of
alveolar macrophages [F4/80, Gr1(low), CD11c(high),
and MHC-II(low)], exudate macrophages [F4/80,
Gr1(high), CD11c(int), and MHC-II(low)], neutrophils (Gr1,
F4/80, and CD11c), CD4 T cells (CD3 and CD4),
and cytotoxic T cells (CD3 and CD8) were assessed
after gating for viable cells. The measured counts of
these cell populations in BALF were related to the total
number of viable cells in BALF that resulted in the total
number of these cell types in BALF.
Histopathology and IHC
Mice were euthanized on day 3 or day 5 after infection,
and lungs were fixed via intratracheal infusion and then
immersion in 10% neutral buffered formalin solution.
Tissues were embedded in formalin, sectioned, and
stained with H&E, with serial histologic sections
stained IHC to determine the distribution of influenza
virus antigen in the lung using hematoxylin as counter-
stain. For IHC, goat primary polyclonal antibody (US
Biological, Swampscott, MA) against anti-influenza A,
USSR (H1N1) was used 1:1000 on tissue sections sub-jected to antigen retrieval for 30 minutes at 98°C [Tar-
get Retrieval Solution (pH 9); Dako Corp., Carpinteria,
CA]. To quantify the extent of viral infection in the lungs,
digital images of whole lung sections stained for viral anti-
gen were first captured using the Aperio ScanScope XT
Slide Scanner (Aperio Technologies, Inc., Vista, CA); then
both uninfected and virus-positive regions were outlined
manually, and areas determined using ImageScope soft-
ware (Aperio Technologies, Inc.).
Results
Mutation Y89F within A/NS1 Disrupts the
Functional SH2bm and Results in Reduced
Replication Fitness
Before studying the functional consequences of disrupt-
ing the SH2bm in A/NS1, we confirmed the altered bind-
ing properties caused by introduction of the mutation
Y89F. For this purpose, we compared a PR8 A/NS1 Y89F
virus (PR8 Y89F) and the corresponding wild-type virus
(PR8 wt) with regard to the well-characterized interaction
of A/NS1 with the regulatory subunit p85 of PI3K.16 The
mutation Y89F resulted in impaired A/NS1–p85 interac-
tion (Figure 1A) and strongly attenuated activation of
PI3K signaling, as indicated by a strong reduction in
phosphorylation of PI3K effector kinase Akt20 in human
(Figure 1B) and mouse (Figure 1F, upper panel) lung
epithelial cells. This confirmed the loss of a functional
SH2bm within A/NS1 by point mutation of the crucial
tyrosine residue at position 89. Focusing on the functional
consequences of disrupting the SH2bm, we examined
the replication ability of the PR8 Y89F virus in comparison
with the wild-type virus. Growth kinetics in A549 human
lung epithelial cells (Figure 1C) and ASB XIV mouse lung
epithelial cells (Figure 1F, lower panel) revealed clearly
reduced progeny virus titers of the PR8 Y89F mutant
virus. Although interaction of A/NS1 with PI3K was dis-
rupted, we could not observe any effects of the mutation
on events during replication described to be PI3K regu-
lated, such as export of viral ribonucleoproteins or pre-
vention of premature apoptosis20 (data not shown).
Therefore, we further focused on additional functions of
A/NS1. The protein is well described as a suppressor of
antiviral signaling.5 Therefore, we wondered whether the
mutation Y89F changes the inhibitory properties of the
protein. We investigated the induction of various cyto-
kines and chemokines on infection with wild-type and
mutant virus. The wild-type virus induced antiviral cyto-
kines such as IFN- or IL-6 more efficiently than did
PR8 Y89F (Figure 1D), correlating with reduced prog-
eny virus titers of the mutant virus (data not shown).
Measurement of the mRNA level of CCL5, TNF-, and
MIP-1 revealed elevated mRNA levels after PR8 wt
compared with PR8 Y89F virus infection as well (data
not shown). These data indicate that reduced levels of
some cytokines and chemokines are most likely a con-
sequence of reduced levels of progeny virus rather
than a direct effect of the mutated A/NS1 on cytokine
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effect of the A/NS1 Y89F mutant on cytokine expres-
sion in the absence of infection. We overexpressed the
wild-type and mutant versions of A/NS1 and stimulated
the cells with genomic vRNA purified from virus parti-
cles. Stimulation of control cells with vRNA increased
the mRNA level of IFN- or IL-6, whereas this induction
was reduced by both expression of wild-type and
A/NS1 Y89F viruses to the same extent (Figure 1E),
demonstrating that the mutation Y89F does not disrupt
the inhibitory properties of A/NS1 on vRNA-induced
antiviral signaling. Investigation of CCL5, TNF-, and
MIP-1 mRNA levels confirmed the results for IFN-
and IL-6 (data not shown). Considered together, our
data thus far show that the mutation Y89F within A/NS1
disrupts the function of the SH2bm, resulting in re-
duced replication ability in human and mouse lung
epithelial cells. However, the mutation does not alter
known PI3K functions in the infected cell, and does not
interfere with the well-established inhibitory potential of
A/NS1 on induction of antiviral signaling.Mutation Y89F within A/NS1 Strongly Reduces
Virulence in an in Vivo Mouse Model
Our results clearly confirm previous findings about the
growth disadvantage of an A/NS1 Y89F mutant IAV virus in
cell culture experiments.16 Nevertheless, until now, no in vivo
data existed about the effect of this SH2bm on IAV virulence.
Using the mouse infection model, we investigated the
virulence of the PR8 Y89F virus in comparison with the
corresponding PR8 wt virus by analyzing weight loss and
lethality after infection. Using an intranasal infectious
dose of 103 PFU per mouse, all mice survived when
infected with PR8 Y89F, in contrast to 100% lethality after
infection with the PR8 wt virus (Figure 2A). Correspond-
ingly, animals infected with wild-type virus lost weight
consistently from day 3 until death (data not shown). In
strong contrast, mice infected with the PR8 Y89F virus
started to lose weight at day 5, to a maximum loss of
approximately 15%, on average, followed by weight gain
starting on day 9 and reaching the starting weight at day
Figure 1. Disruption of functional SH2bm within
A/NS1 by the mutation Y89F impairs virus replica-
tion. A: At 24 hours after transfection with a plas-
mid encoding p85, 293 cells were infected with
PR8 wt virus or the corresponding mutant virus
PR8 Y89F [multiplicity of infection (moi)  5] or
were left uninfected for 8 hours, and were subse-
quently harvested. Cell lysates were subjected to
immunoprecipitation (IP) using an anti-A/NS1 an-
tibody. As control, mouse serum was used for im-
munoprecipitation. Co-immunoprecipitated p85
was detected usingWestern blot analysis. Levels of
equal protein precipitation of A/NS1 in the immu-
noprecipitates were verified using specific anti-
bodies. A/NS1 and endogenous p85 of crude cell
lysates served as control. B: A549 cells were in-
fected with PR8 wt or PR8 Y89F virus (moi 5) for
the times indicated or were left uninfected. Phos-
phorylated Akt (pS473) was detected using West-
ern blot analysis. Viral protein synthesis was visu-
alized using A/NS1 Western blot analysis. Equal
protein loads were verified using Akt and ERK2
antibodies. C andD: A549 cells were infected with
PR8 wt or PR8 Y89F virus [moi  0.01 (C) and
moi  5 (D)]. C: At 8, 24, and 32 hours after
infection, supernatants were collected and assayed
for progeny virus yields in standard plaque titra-
tions. D: At 8 hours after infection, the mRNA
levels of IFN- and IL-6 were measured using real-
time qPCR and depicted as n-fold of the uninfected
sample. The housekeeping gene GAPDH served
as internal standard. E: At 24 hours after transfec-
tion with plasmids encoding PR8-NS1-wt and PR8-
NS1-Y89F, or empty vector for control, A549 cells
were transfected with virion-extracted vRNA. At 6
hours after transfection, mRNA levels of IFN- and
IL-6 were measured using real-time qPCR and vi-
sualized as n-fold of the empty vector transfected
and unstimulated samples. The housekeeping gene
GAPDH served as internal standard. F: Upper
panel:ASBXIV cells (murine lung epithelial cell line)
were infected with PR8 wt or PR8 Y89F virus
(moi  5) for 8 hours or were left uninfected.
Phosphorylated Akt (pS473) was detected using
Western blot analysis. Viral protein synthesis was
visualized using A/NS1 Western blot analysis.
Equal protein loads were verified using Akt and
ERK2 antibodies. Lower panel: ASB XIV cells
were infected with PR8 wt or PR8 Y89F virus
(moi  0.1). At 8 and 24 hours after infection,
supernatants were collected and assayed for prog-
eny virus yields in standard plaque titrations.15 (data not shown). The MLD50 obtained for the PR8 wt
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mutant virus, clearly illustrating the large difference in
virulence (Figure 2B).
In addition, we measured the accumulation of virus
particles in the entire lung and the BALF. Our data re-
vealed a significantly reduced amount of progeny virus in
the lungs (Figure 2C) and BALF (Figure 2D) of PR8 Y89F–
infected animals at all times investigated. Hence, our
data illustrate a dramatic decrease in virulence accom-
panied by a strong reduction in progeny virus titers as a
consequence of a single point mutation in A/NS1 that
disrupts the SH2bm of the protein.
Cytokine and Chemokine Levels in the Lung
Almost Reflect Virus Replication
Many previous studies have investigated the onset and
severity of cytokine and chemokine expression in response
to IAV infection. In addition to findings that demonstrated a
timely interplay of IAV infection and cytokine and chemokine
profiles,33–35 several studies have focused on the effect of
cytokine responses on disease symptoms and host de-
fense, in particular H5N1 infection.36,37 Therefore, we inves-
tigated the expression of several cytokines and chemokines
in mouse lungs infected with PR8 wt virus and the mutant
PR8 Y89F virus at different times after infection (days 1, 3,
and 5). At day 1, we observed amarginal increase in mRNAlevels after infection with the PR8 Y89F virus, although the
differences were too small to be statistically significant (Fig-
ure 3). On days 3 and 5 after infection, the mRNA levels of
all investigated cytokines and chemokines were increased
after infection with both the wild-type virus and the PR8
Y89F virus when compared with the PBS-injected control
mice, reaching a plateau between day 3 and 5 after inoc-
ulation. On day 3 after infection, we found a statistically
significant increase in levels of MCP 1, TNF-, MIP-1, and
MIP-1 mRNA after infection with the PR8 wt virus (Figure
3). Considered together, our data demonstrate a correlation
between progeny virus titers (Figure 2) and the correspond-
ing up-regulation of cytokine and chemokine mRNA levels
(Figure 3), without any evidence for increased or acceler-
ated induction of immunity on PR8 Y89F virus infection as an
explanation for the reduced virus accumulation.
Migration of Immune Cells into the Airways of Mice
Infected withWild-Type Virus Is Increased as
Compared with Mice Infected with PR8 Y89F Virus
The major function of chemokines such as MCP or
MIP-1 is the attraction of immune cells to the site of
inflammation.38 Revealing statistically significantly ele-
vated cytokine and chemokine mRNA levels in mouse
lungs infected with PR8 wt virus on day 3 after infection
Figure 2. Mutation Y89F within A/NS1 significantly de-
creases virulence in mice. A and B: Five mice per group were
infected intranasally with 103 PFU/mouse (A) or 102 to 106
PFU/mouse (B) of PR8 wt or mutant virus PR8 Y89F, and
were monitored for survival for 15 days. A: Kaplan-Meier
survival curve analysis was performed using the log rank
test; the statistical significance of the differences (*P  0.05).
B: Results of the various investigated virus dosages are de-
picted as number of surviving mice/number of infected
mice. The mouse lethal dose (MLD50) was calculated ac-
cording to the protocol of Reed and Muench protocol.31 C
and D: Eight (C) or nine (D) mice per group were infected
intranasally with PR8 wt or PR8 Y89F virus (103 PFU). Virus
titers of infected lungs were determined at 1, 3, and 5 days
after infection in standard plaque titrations (C), and virus
titers in BALF were assayed at 3 and 5 days after infection
(D). Each dot represents the result of one mouse, and gray
bars indicate the mean of all mice per group. Statistical
significance of the differences was assessed using the t test.
*P  0.05.prompted us to focus on the inflammatory status of the
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immune cells into the lung, we examined the cellularity of
BALF. The BALF was collected on day 3 and 5 after
infection, and the total cell count in the BALF was deter-
mined after red blood cell lysis. Although, infection with
both viruses resulted in increased cellularity in the BALF
compared with PBS-infected mice (Figure 4A), the total
cellularity was slightly increased after infection with the
PR8 wt virus at day 3 after infection (Figure 4A, left panel)
and was clearly and statistically significantly enhanced
by twofold at 5 days after virus inoculation (Figure 4A,
right panel). Following the general investigation of cellu-
larity in BALF, we addressed which specific immune cell
populations were altered after infection. Starting with the
pool of alveolar macrophages, the primary cell type pres-
ent in BALF in naïve mice,39 we observed a statistically
significant reduction of alveolar macrophages at day 3
(see Supplemental Figure S1 at http://ajp.amjpathol.org)
and day 5 after infection (Figure 4B) in BALF from mice
infected with PR8 wt virus compared with those infected
with PR8 Y89F or PBS. In contrast, cell counts for exudate
macrophages and neutrophils were enhanced after in-
fection with PR8 wt virus and PR8 Y89F when compared with
those in naïve mice. Comparison of mice infected with PR8 wt
virus and PR8 Y89F demonstrated that significantly elevatedcounts for exudate macrophages (approximately sevenfold)
and neutrophils (approximately twofold) were detectible at day
3 (see Supplemental Figure S1 at http://ajp.amjpathol.org) and
day 5 (Figure 4B) after infection with wild-type virus, demon-
strating that the attraction of phagocytes into the lung was
increased. Finally, we investigated the early onset of the adap-
tive immunity by measuring the numbers of CD3 CD4 and
CD3 CD8 T cells in BALF as performed previously.40–42
This revealed that counts for CD3 CD4 and CD3 CD8 T
cells are equally increased inBALFafter PR8wt andPR8Y89F
virus infection on both day 3 after infection (see Supplemental
Figure S1 at http://ajp.amjpathol.org for CD3CD8, and Sup-
plemental Figure S2 at http://ajp.amjpathol.org for CD3
CD4) and day 5 after infection (Figure 4B for CD3 CD8
and Supplemental Figure S2 at http://ajp.amjpathol.org for
CD3CD4). Focusing on the induction of adaptive immunity
in more detail, infection of animals with 1xMLD50 resulted in
roughly similar weight loss and total cellularity in BALF, but
increased counts for CD3 CD4 and CD3 CD8 T cells in
BALF of PR8 Y89F virus–infectedmice on day 3 after infection
(see Supplemental Figure S3, A–C, at http://ajp.
amjpathol.org). The obtained data illustrate that infection with
the PR8 wt virus results in increased cellularity in BALF com-
paredwith PR8 Y89F infection and that, in particular, migration
Figure 3. Cytokine and chemokine production
is decreased in PR8 Y89F virus–infected lungs.
Ten mice per group were infected intranasally
with 103 PFU of PR8 wt virus or the mutant virus
PR8 Y89F, or PBS for control. On days 1, 3, and
5 after infection, the total lungs were isolated,
and the mRNA levels of MCP-1, TNF-, IL-6,
MIP-1, and MIP-1 were measured using RT-
qPCR, depicted as n-fold of the PBS-inoculated
mice on day 1. The housekeeping gene GAPDH
served as internal standard. Each dot represents
the result of one single mouse, and gray bars
indicate the mean of all mice per group. Statis-
tical significance of the differences was assessed
using the t test. *P  0.05, with Bonferroni cor-
rection for multiple comparisons. WT, wild type.of phagocytes such as exudatemacrophages andneutrophils
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responses in lungs after infection with the PR8 wt virus.
Markers for Pathologic Changes in the Lung Are
Increased after Infection with PR8 wt Virus
Compared with Infection with PR8 Y89F Virus
Host immune reactionsmustmaintain a balance between pro-
tection of the infected individual and immunopathology.43 Sev-
eral previous reports have proposed the massive infiltration of
exudate macrophages and neutrophils as a cause of immu-
nopathologic changes in the lung, ultimately leading to
death.41,44,45 Furthermore, influenza virus infection itself leads
to cytolytic death of infected cells at 20 to 40 hours after
infection.46 Therefore, we sought to determine whether the
observed decrease in virus accumulation and inflammation
after PR8 Y89F virus infection results in reduced levels of lung
injury.Measurement of total protein concentration in BALF as a
marker for alveolar-capillary leakage revealed increased evi-dence for lung injury on day 3, which was even more pro-
nounced and statistically significant on day 5, in mice infected
with the PR8 wt virus (Figure 5A). Consistent with enhanced
concentrations of total protein in BALF, the level of LDH as a
marker for tissue damage 45,47,48 was also significantly higher
(Figure 5B). These data provide evidence for a correlation
between decreased lung pathology and decreased death of
PR8 Y89F–infected mice.
Strong Restriction of Virus Spread in the Lungs
of PR8 Y89F–Infected Mice
After identifying less severe pathologic changes on the
level of total protein and LDH concentration in BALF
(Figure 5), we performed histologic examinations of in-
fected mouse lungs on days 3 and 5 after infection.
Initially, we focused on the total distribution of IAV antigen
in the entire lung. Examination of antigen-positive areas
Figure 4. Infiltration of immune cells in BALF is
increased after PR8 wt virus infection. A and B:
Nine mice per group were infected intranasally
with 103 PFU PR8 wt virus or mutant virus PR8
Y89F. PBS-inoculated mice served as control.
Bronchoalveolar lavage was performed on day 3
(A) and 5 (A and B) after infection. A: After lysis
of red blood cells, the total cell count of BALF
was determined; mean values of all mice per
group are shown. B: The mouse BALF was as-
sayed via flow cytometry for the number of al-
veolar macrophages, exudate macrophages,
neutrophils, and CD3 CD8 T cells. Each dot
represents the result of one single mouse, and
gray bars indicate the mean of all mice per
group. Statistical significance of the differences
was assessed using the t test. *P  0.05, with
Bonferroni correction for multiple comparisons.revealed that the extent of virus spread in the entire lungs
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both day 3 and day 5 after infection (Figure 6A). Quan-
tifying the mean of antigen-positive areas as a percent-
age of the total lung field illustrated the dramatic dif-
ferences in virus distribution between PR8 wt virus and
the mutant virus. Almost 90% of the lung field in mice
infected with the PR8 wt virus was antigen positive for
IAV, compared with approximately 35% of the lung
field in PR8 Y89F virus–infected mice on day 5 after
infection (Figure 6B).
Mutation Y89F in A/NS1 Results in Restricted
Tropism and Strongly Decreased Pathologic
Alterations in Mouse Lung
The observed attenuated spread of the PR8 Y89F virus
prompted us to investigate the epithelial cell tropism of
the PR8 wt and the PR8 Y89F viruses. In addition, we
focused on examining pathologic changes within the
lung on days 3 and 5 after infection. In lungs infected with
PR8 wt virus, necrotizing lesions and viral antigen were
already observed in all areas of the trachea, bronchi and
bronchioles, and alveoli at day 3 after infection (see Sup-
plemental Figure S4 at http://ajp.amjpathol.org). In con-
trast, we found that the extent and severity of influenza
infection and associated pulmonary pathology was much
milder in lungs of mice infected with PR8 Y89F virus (see
Supplemental Figure S4 at http://ajp.amjpathol.org). The
inflammatory infiltrates in PR8 Y89F–infected mice of-
ten formed prominent perivascular cuffs, which primar-
ily consisted of lymphocytes rather than the macro-
phages and granulocytes that were predominant in thelungs infected with PR8 wt virus. Another striking differ-
ence observed in the lungs of PR8 Y89F–infected mice
was the absence of degeneration and necrosis in the
pseudostratified respiratory epithelium of the trachea and
the bronchi and bronchioles, which was associated with
near absence of viral antigen in these cells. In contrast,
no notable differences in virus tropism were detected in
alveoli, where virus antigen was widely distributed in type
II pneumocytes and macrophages in both lungs infected
with wild-type and mutant virus (see Supplemental Figure
S4 at http://ajp.amjpathol.org).
By day 5 after infection, lesions in PR8 wt virus–in-
fected lungs were similar in most respects to those ob-
served on day 3 after infection, but were more extensive
than those observed at the earlier time and involved most
of the lung parenchyma (Figure 7). At day 5 after infec-
tion, almost all bronchioles showed some degree of de-
generative and necrotic changes, which ranged from
cytoplasmic vacuolization and nuclear pyknosis to se-
vere attenuation or loss of respiratory epithelium (Figure 7).
In many bronchioles, necrosis of respiratory epithelium re-
sulted in areas that showed mixtures of denudation, atten-
uation, regeneration, and squamousmetaplasia of surviving
respiratory epithelium. In most bronchioles, influenza virus
antigen was detected in almost all remaining respiratory
epithelial cells and within necrotic lumen contents. Although
the extent and severity of PR8 Y89F infection and the asso-
ciated pulmonary pathology increased markedly between
day 3 and day 5 after infection, the outcome was still much
milder and more localized than in lungs infected with the
wild-type virus (Figure 7). In contrast to marked necrotizing
Figure 5. Less severe pathologic changes in
PR8 Y89F–infected mouse lungs. A and B: Five
mice per group were infected intranasally with
103 PFU PR8 wt virus or mutant virus PR8 Y89F,
or PBS for control. At 3 and 5 days after inocu-
lation, BALF was collected. Measurement of total
protein concentration via the Bradford assay (A)
and LDH concentration via lactate dehydroge-
nase assay (B) served as markers for pathologic
changes in the lung. Mean values of all mice per
group are shown. Statistical significance of the
differences was assessed using the t test. *P 
0.05, with Bonferroni correction for multiple
comparisons.bronchiolitis in the PR8 wt virus–infected lungs, there was a
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thelium of the trachea and bronchi and bronchioles in PR8
Y89F–infected lungs. In addition, all tracheal and bronchial
airway epithelium was negative for viral antigen, and almost
all bronchioles were also histologically normal and negative
for virus antigen. A few scattered bronchioles contained
variable numbers of respiratory epithelial cells that were
positive for virus antigen; however, these showed no signs
of degeneration or necrosis, although some bronchiolar ep-
ithelium was slightly hypertrophic (Figure 7).
Alveolar lesions were distributed throughout the lung
after PR8 wt virus infection, but varied in severity. Virus
antigen was widely dispersed in alveoli, diffusely lining
all alveolar surfaces, but was highly concentrated in
type II pneumocytes and alveolar macrophages. In
virus-positive areas, alveoli typically contained ne-
crotic cell debris and inflammatory cell infiltrates,
which consisted largely of neutrophils and macro-
phages. In many areas, the extensive alveolitis was
characterized by thickened septae and widespread
necrosis and sloughing of alveolar lining cells, with
associated hyaline membrane formation (Figure 7). In
contrast to the wild-type virus, the overall extent of infec-
tion and alveolitis was relatively mild in PR8 Y89F virus–
infected lungs, with viral antigen present within alveolar
macrophages and both type I and type II pneumocytes in
the affected alveoli. Nevertheless, the degree of lympho-
cytic inflammation in perivascular space and septae was
greatly increased when compared with the wild-type vi-
rus (Figure 7). Moreover, these inflammatory infiltrates
contained relatively few macrophages and granulocytes,with the reduced numbers of neutrophils in the intersti-
tium, bronchioles, and alveoli, which correlated with the
marked reduction in numbers of necrotic epithelial cells
in airways and alveoli.
Considered together, our results clearly show that the
SH2bm within A/NS1 of IAV is unambiguously crucial for
virus virulence in an in vivo mouse model. Thus, we iden-
tified the SH2bm within A/NS1 as an essential motif for the
A/NS1 to fulfill its functions as a major pathogenicity de-
terminant of IAV.
Discussion
The ongoing potential of IAV to cause seasonal epidem-
ics classifies IAV as a major threat to health in humans.
Amplifying this concern as a life-threatening agent, out-
breaks such as the 2009 pandemic H1N1 virus or human
infections with highly virulent H5N1 variants clearly em-
phasize the need for further knowledge about the bio-
logic characteristics of influenza virus infections. The NS1
protein of IAV (A/NS1) is considered as a crucial patho-
genicity determinant,5,49 and is well studied as a blocker
of host signaling to limit the cellular immune response.
Several studies of the immunosuppressive properties of
A/NS1 have suggested that direct binding of A/NS1 to
cellular proteins is one mechanism of A/NS1 action.9–11
As a result of these studies, binding of A/NS1 to cellular
proteins and the binding motifs involved20 have become
topics of major interest. The A/NS1 protein carries an
Figure 6. Total virus distribution is attenuated in PR8 Y89F
virus–infected mouse lungs. A: Four mice per group were
infected intranasally with 103 PFU PR8 wt virus or mutant
virus PR8 Y89F. PBS-inoculated mice served as control. At 3
and 5 days after infection, the lungs were harvested, fixed,
embedded, sectioned, and stained IHC with an antibody
against anti-influenza A (H1N1) to determine the distribution
of influenza virus antigen in the entire lung. Hematoxylin
served as counterstaining for IHC staining. Representative
images for each group are shown. B: For quantification of
the extent of viral infection in the lungs, digital images of
stained whole lung sections of all four mice per group were
captured (20 magnification), and both uninfected and vi-
rus-positive regions were outlined manually and areas de-
termined using Aperio ImageScope software. Mean values
for all mice per group are shown. Statistical significance of
the differences was assessed using the t test. *P  0.05.RNA-binding domain and several protein–protein interac-
tative im
logic alt
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that is, one SH2bm and two SH3bm.20 SH2 and SH3
domains are common protein interaction motifs in-
volved in cellular signal transduction. SH3 domains
interact with proteins carrying proline-rich motifs
(SH3bm), whereas phosphotyrosine residues carrying
Figure 7. Epithelial cell tropism and lung pathology are limited in PR8 Y89
PR8 wt virus or mutant virus PR8 Y89F, or PBS for control. At 5 days after infec
analysis. Serial sections were stained at IHC with an antibody against anti-infl
epithelium. Hematoxylin served as counterstain for IHC staining. Represen
section IHC staining 40 magnification). Arrows indicate significant pathomotifs (SH2bm) bind to SH2 domains.25 Several stud-ies have focused on the effect of A/NS1 SHbm on
A/NS1 functions and/or IAV virulence.16,18,26,27,50 Tak-
ing into account that the SH2bm within A/NS1 is highly
conserved, even including all highly pathogenic hu-
man H5 strains and 2009 pandemic H1N1 strains, we
focused on the effect of this binding motif in IAV viru-
infected mice. Four mice per group were infected intranasally with 103 PFU
lungs were fixed, embedded, sectioned, and stained with H&E for histologic
(H1N1) to assay the influenza virus antigen distribution along the respiratory
ages for each group are shown (60 magnification except the bronchiole
erations in lungs infected with PR8 wt.F virus–
tion, the
uenza Alence.
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the regulatory subunit p85 of PI3K,16 and subsequently
blocking of PI3K activation by the mutation Y89F within
A/NS1, revealed the loss of function of the SH2bm, re-
sulting in reduced replication ability of the PR8 Y89F virus
in human and murine epithelial cells. These data are in
line with results obtained by using reverse genetic sys-
tems to introduce the same mutation in A/NS1 proteins of
other virus strains (data not shown).16
That impaired A/NS1-induced PI3K activity correlated
with decreased replication capability of PR8 Y89F
prompted us to investigate whether known PI3K-regu-
lated events during the IAV life cycle are altered after
infection with the mutant virus.20 Summarizing these
studies, we did not observe major differences in apopto-
sis induction or viral ribonucleoprotein export from the
nucleus when comparing wild-type and A/NS1 mutant
infections (data not shown). This may be indicative of a
yet unknown function of PI3K signaling that affects the
viral life cycle. However, we cannot rule out that, due to the
loss of the functional SH2bm in PR8 Y89F, binding of A/NS1
to other yet unknown SH2 domain–bearing proteins may be
hampered in addition to the well-described A/NS1–p85
interaction. This may not be a protein that is involved in
A/NS1-mediated suppression of antiviral signaling because
we did not observe any differences between wild-type and
mutant A/NS1 in blocking vRNA-induced antiviral signaling.
Several other A/NS1-regulated steps during virus replica-
tion,5 such as regulation of polymerase activity51,52 or in-
volvement in virus particle formation,53 may be affected by
disruption of the SH2bm within A/NS1. However, precise
studies are required to clarify the mechanistic basis for the
attenuated phenotype.
A major objective of our study was to obtain insight into
the role of the highly conserved SHbm2 for IAV virulence
in an in vivo mouse model. Monitoring disease markers
such as weight loss and death revealed dramatically
decreased virulence for the PR8 Y89F virus, which is
further evidenced by a large increase in the MLD50 and
the decreased progeny virus titers in total lung and BALF.
Several recent studies have focused on the involvement
of four C-terminal residues of NS1, described as the PDZ
ligand domain,5 in IAV virulence.54–56 The present study
contributes to understanding of the role of A/NS1 SH2bm
in IAV pathogenicity in vivo.
To clarify the in vivo events that are the basis of the
strongly reduced virulence of PR8 Y89F virus, we fo-
cused on induction of immunity after infection of mice.
The reduced cytokine and chemokine induction on day 3
after infection correlated with reduced virus titers in lungs
infected with PR8 Y89F. Total cellularity of BALF was
reduced after infection with the mutant virus, indicating
that the enhanced virulence of the PR8 wt virus is accom-
panied by a strong influx of immune cells to the lung.
Analysis of the cellular composition of the BALF revealed
that the pool of resident alveolar macrophages was sig-
nificantly reduced, and the counts for exudate macro-
phages and neutrophils were significantly increased after
PR8 wt virus infection, together illustrating an increased
inflammatory response in the lungs infected with PR8 wt.
The turnover of macrophages in the inflamed lung wasinvestigated earlier, illustrating depletion of alveolar macro-
phages and recruitment of exudate macrophages after in-
flammation induction.57 Herold et al41 demonstrated partial
reduction of alveolar macrophage counts and the recruit-
ment of exudate macrophages and neutrophils in BALF
after IAV infection as well. Furthermore, histologic analyses
of infected lungs confirmed the highly increased numbers
of macrophages and neutrophils in lungs infected with the
wild-type virus. Collectively, our data argue for an interplay
of increased virus accumulation, leading to increased cyto-
kine and chemokine induction and enhanced infiltration of
immune cells into the inflamed lung after infection with PR8
wt virus compared with PR8 Y89F virus.
With respect to induction of adaptive immunity, lym-
phocytes migrate into the BALF and lung interstitium after
influenza virus infection.42,58 No differences in counts for
CD3 CD4 and CD3 CD8 T cells in BALF were ob-
served between PR8 wt and PR8 Y89F infections. Never-
theless, by analyzing histologic sections of infected
lungs, an increased number of lymphocytes infiltrating
the lung interstitium in PR8 Y89F virus–infected mice was
observed, which correlated with slightly elevated migra-
tion of CD11c dendritic cells from the lungs to draining
lymph nodes (data not shown). Finally, 1xMLD50 infec-
tions resulted in increased counts for CD3 CD4 and
CD3 CD8 T cells in BALF from PR8 Y89F virus–in-
fected mice. Taken together, we hypothesize that there is
an effect of the mutation Y89F within A/NS1 on the de-
scribed suppressive properties of A/NS1 on induction of
adaptive immunity.8 However, these differences in the
adaptive immune response may not be sufficient to ex-
plain the dramatic differences in virulence of wild-type
and mutant virus.
IAV are lytic viruses that destroy the infected cells.46 In
addition, infiltration of exudate macrophages and neutro-
phils into the lung of IAV-infected animals could be linked
to immunopathologic alterations.41,44,45 Total protein and
LDH as markers for pathologic changes in the lung were
increased in animals infected with the wild-type virus,
providing first evidence for increased pathologic tissue
alterations. Furthermore, massive differences in the se-
verity of disease between PR8 wt and PR8 Y89F virus
infection were observed at histologic analysis. Most im-
pressive, wild-type virus infections produced degenera-
tive and necrotic changes to the point of loss of respira-
tory epithelium in almost all bronchioles, in contrast to the
striking absence of degeneration and necrosis in the
epithelium of the trachea and the bronchi and bronchi-
oles in PR8 Y89F–infected lungs. Furthermore, the exten-
sive alveolitis in PR8 wt virus–infected lungs, which is
accompanied by pathologic changes such as hyaline
membrane formation, as described earlier,59 was much
less severe in A/NS1 mutant virus–infected lungs.
In addition to the reduced severity of pathologic
changes, the extent of PR8 Y89F virus spread in the mouse
lung was decreased, and cellular tropism was strongly re-
stricted to alveoli, essentially sparing bronchiolar epithe-
lium. The hemagglutinin surface protein of influenza viruses
is responsible for the receptor binding specificities (-2,3 or
-2,6 sialic acid), regulating virus tropism.60 Nevertheless,
additional cellular and viral factors are involved in regulation
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ons61 or, as recently published, A/NS1.62 This argues for a
potential indirect role of A/NS1 in regulating virus spread
and, thereby, lung epithelial tropism in the present study. In
support of this hypothesis, the pattern of infected type II
pneumocytes suggests slower spread of the attenuated
A/NS1 mutant between alveoli, which could be the result of
decreased virus replication. The few areas of PR8 Y89F
virus antigen–positive bronchiolar epithelial cells were lim-
ited to the most severely affected regions of the lung, which
suggests that even these cells are susceptible to infection
with the attenuated PR8 Y89F virus if the virus load is suffi-
ciently high. Based on findings of histologic analyses, we
believe that the greater extent of virus antigen–positive cells
and more severe lesions in PR8 wt virus–infected lungs
account for the increased virulence and lethality associated
with infection with the PR8 wt virus. The increased patho-
genicity after infection with the wild-type virus is most likely
based on two interlinked chains of events. First, the in-
creased replication capacity and spread of the PR8 wt
virus itself directly results in pathology, for example, the
necrosis and, thereby, destruction of the bronchiolar ep-
ithelium. Second, the increased infiltration of exudate
macrophages and neutrophils in the lung after infection
with PR8 wt virus also may contribute to lung disease via
deployment of immunopathologic changes, as also ob-
served in earlier studies.41,44,45
Thus, with regard to the effect of SH2bm disruption on
virus virulence, we hypothesize that in a first line, the
reduced virus replication and virus spread directly ac-
counts for the diminished pathogenicity and lethality. In
addition, the mutation Y89F could also lead to impaired
suppressive action of A/NS1 on adaptive immunity by
hampering interactions with SH2 domain carrying cellular
proteins such as PI3K. It should be mentioned in this
context that several previous publications have linked
PI3K to immune regulatory functions.63–66
In summary, our data demonstrate for the first time that
the highly conserved SH2bm of A/NS1 has an impressive
effect on IAV virulence in vivo. These data contribute to
the understanding of the essential role of A/NS1 functions
as a regulator of virus virulence, further fostering A/NS1
as a suitable target for antiviral interventions.
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